ERYTECH Reports Top-line Results of Phase 2b Study of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
748
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML

ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML

Conference call and webcast to take place Monday, December 11th at 10:00 a.m. EST

LYON, France - December 8, 2017 - ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced topline results from its Phase 2b clinical study evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML).

The open-label, randomized, multi-center clinical study, evaluated eryaspase in newly diagnosed AML patients over the age of 65 and unfit for intensive chemotherapy. The study enrolled a total of 123 patients at 30 European sites. The median age of the patients was 78 years. Patients were randomized two-to-one to receive eryaspase in combination with low-dose cytarabine (LDAC) versus LDAC alone. The primary endpoint in this proof-of concept study was overall survival (OS).  The key secondary endpoints included progression free survival, overall response and toxicity. The study was performed in collaboration with Orphan Europe (Recordati Group), ERYTECH's partner for the anticipated commercialization of GRASPA® for the treatment of ALL and AML in Europe.

The study did not meet its primary endpoint of overall survival (OS). The OS Hazard Ratio (HR) was 1.06 (95% CI; 0.70, 1.61). When adjusting for minor imbalances in the main prognostic factors at baseline (age, karyotype and FAB status), the OS HR was 0.98 (95% CI; 0.64, 1.50). The median number of months on treatment was less then 2 months in both treatment arms. The toxicity profile was acceptable and consistent with previously reported data for eryaspase.

" These data reflect the complexity of this disease, particularly in the older age group. " commented Iman El-Hariry, MD, PhD, Chief Medical Officer of ERYTECH. " While we are disappointed with the outcome, we are reassured with the safety profile of eryaspase in these very frail and elderly patients. "

Gil Beyen, Chairman and CEO of ERYTECH, added, " Although clearly disappointing, these results do not change our commitment to the development of the eryaspase product candidate. Eryaspase has shown positive safety and efficacy results in the treatment of pancreatic cancer and acute lymphoblastic leukemia and we remain committed to bringing this treatment option to patients in these and potential other indications. "

ERYTECH will hold a conference call and webcast on Monday, December 11 th at 10:00 am EST to discuss the results of this study. The full dataset will be discussed at a scientific congress in 2018.

Investors and analysts wishing to participate can access the call via the following teleconferencing numbers:

USA: +1 833 8186807                      United-Kingdom: +080 00323836 Switzerland: +080 0561782             Germany: +080 01815287 France: +080 5081485                     Belgium: +080 073308 Sweden: +020 798505                     Finland : +080 0412874 Netherlands: +080 00200089

Password : 6983889

The webcast can be followed live online via the following link:

Webcast Link:  https://edge.media-server.com/m6/p/o2fziqc6

An archive of the webcast will be available for 90 days on the "Webcast" section of the Company's investor relations site at www.erytech.com .

Additionally, a replay of the call will be available for 7 days. To listen to the replay, please dial:

USA: +1 404 537 3406 Participant Password: 6983889

About acute myeloid leukemia (AML)

AML is a form of acute leukemia or blood cancer that results from the improper maturation of myeloid stem cells leading to the production of myeloblasts.  The increasing numbers of abnormal blasts crowd out healthy cells in bone marrow (resulting in infection, anemia, and bleeding) and can spread to other parts of body. With about 40,000 new patients per year in Europe and the United States, AML is the most common type of acute leukemia. Affecting mainly the adult and senior patient population, the median age of patients diagnosed with AML is approximately 67 years, and AML represents one of the highest mortality rates among all type of cancers and an important unmet medical need.

About ERYTECH and eryaspase (GRASPA®): www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's initial focus is on the development of products that target the amino acid metabolism of cancer, depriving them of nutrients necessary for their survival.

The Company's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status. Eryaspase aims to provide L-asparaginase to patients who cannot tolerate current non-encapsulated asparaginases.

In addition to eryaspase, ERYTECH is developing two other product candidates, erymethionase and eryminase, that focus on using encapsulated enzymes to target cancer metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP)and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers ( www.amf-france.org ), also available on ERYTECH's website ( www.erytech.com ) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

CONTACTS 

ERYTECH     Naomi Eichenbaum Director of Investor Relations The Ruth Group Lee Roth Investor relations Kirsten Thomas Media relations NewCap Julien Perez Investor relations Nicolas Merigeau Media relations
  +33 4 78 74 44 38 +1 917 312 5151 naomi.eichenbaum@erytech.com   +1 646 536 7012 lroth@theruthgroup.com +1 508 280 6592 kthomas@theruthgroup.com   +33 1 44 71 98 52 erytech@newcap.eu
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 112

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Shenzhen's Vertical Factories Put Robotics on Fast Track

Updated Category News Views 26

A truck climbing to a ninth-floor factory is the sort of detail that cuts through the usual innovation fog. Shenzhen's Honghualing industrial base in Nanshan is built around that odd-looking reality: keep engineers, component makers, automated lines and test customers stacked close together, then squeeze time out of the process. For anybody watching robotics, LiDAR and...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 187

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Fox Hill Steel Marks a Long Public-Building Road Ahead

Updated Category News Views 70

A signed steel beam is a fine civic moment, but it is not the finish line. Burlington’s new Fox Hill Elementary School has reached its topping-off milestone, with the structural steel now in place for a 91,000-square-foot, two-story facility intended to serve roughly 325 kindergarten-through-fifth-grade students. That is tangible progress, the sort nobody can fake with...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 195

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
ArchiPro Enters U.S. Design Market With Curated Bet

Updated Category News Views 56

Blue-chip furniture and glossy project photos are not a moat by themselves, no matter how hard a platform tries to make them look like one. But ArchiPro’s full U.S. launch deserves a closer look because it arrives with something many would-be marketplace operators lack: more than a decade of operating history in New Zealand and Australia. A Three-Sided Machine Meets...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 100

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 170

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Leatt Sets Its Virtual 2026 Shareholder Meeting Date

Updated Category News Views 73

A calendar notice is not a catalyst, but ignoring the calendar is how shareholders miss the small moments that matter. Leatt Corporation has scheduled its 2026 virtual annual general meeting of stockholders for Friday, November 20, at 11:00 AM Eastern Time. For holders of OTCQB:LEAT, this is a basic corporate-governance event, not a new product launch or a financial...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 96

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Investing During Market Peaks Explained

Updated Category News Views 291

Understanding Market Behaviors: Peaks and Investment Strategies The stock market has a tendency to rise over time. Historically, whether viewed through six-month, one-year, or even five-year lenses, the S&P 500 has consistently produced positive returns. This pattern holds true even as the market reaches record highs, a phenomenon that has drawn attention from analysts....

Continue Reading
Holborn Assets Launches Innovative App for Wealth Management

Updated Category News Views 212

Holborn Assets Introduces a Cutting-Edge Financial App In a significant move that underscores its commitment to digital transformation, Holborn Assets has rolled out an innovative app aimed at optimizing wealth management for its clients. This comprehensive financial management solution is specifically designed to provide users with seamless access to their financial...

Continue Reading
Growth of Mobivity's Connected Rewards in the Retail Sector

Updated Category News Views 137

Enhancing Customer Engagement with Connected Rewards Mobivity Holdings Corp. (OTCQB: MFON) has recently witnessed a remarkable surge in its Connected Rewards technology adoption among convenience store retailers. This significant development highlights how effective customer engagement solutions can reshape the retail landscape, particularly during the recent quarter. A...

Continue Reading
Coherent Boosts Silicon Carbide Production for AI and Datacenters

Updated Category News Views 192

Coherent Enhances Its Silicon Carbide Platform Coherent Corp. (NYSE: COHR), a global leader in photonics, has recently made significant strides in its development of silicon carbide (SiC) technology to meet the growing thermal efficiency needs of artificial intelligence in datacenter infrastructures. This advancement represents a major milestone for the company in its...

Continue Reading
World Bank's Commitment to Bangladesh: Over $2 Billion for Reforms

Updated Category News Views 140

World Bank Commits Over $2 Billion to Bangladesh The World Bank has recently made a major announcement regarding financial support for Bangladesh, pledging more than $2 billion for the current fiscal year. This funding is designed to help accelerate ongoing reform efforts, improve response to natural disasters, and enhance healthcare services and air quality throughout...

Continue Reading